<DOC>
	<DOCNO>NCT00162175</DOCNO>
	<brief_summary>A Phase 3 , Randomized , Double-blind , Placebo Controlled , Multicenter Trial Evaluate Safety Efficacy BMS-298585 Combination Glyburide Therapy Subjects Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Sulfonylurea Therapy Alone .</brief_summary>
	<brief_title>PPAR-COMBO With Sulfonylurea</brief_title>
	<detailed_description />
	<criteria>Type 2 Diabetes , HbA1c &gt; 7.0 % &lt; 10.0 % , mean serum triglyceride &lt; 600 mg/dL , body mass index &lt; 41 kg/m2 , fast cpeptide . 1.5 ng/mL . History MI ( myocardial infarction ) , coronary angioplasty bypass graft ( ) , valvular disease repair , unstable angina pectoris , transient ischemic attack ( TIA ) , cerebrovascular attack , cerebrovascular accident ( CVA ) within 6 month , congestive heart failure ( NYHA Class III IV , uncontrolled hypertension , history renal disease , peripheral vascular disease ( PVD ) , pulmonary disease , gastrointestinal disease , active liver disease endocrine disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>